Strategies to improve tolerability of rivastigmine: a case series.
Cholinesterase inhibitors, which act by inhibiting the degradation of acetylcholine in the brain, form the mainstay of therapy for AD. Predominant adverse events are cholinergic in nature, the most frequent being gastrointestinal side effects. Here we present a case series of patients with dementia who were treated with non-standard titration regimens of oral rivastigmine in order to achieve improved tolerability.
Venkatesh
K
K
Bullock
R
R
Akbaş
A
A
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D005260:Female; D005767:Gastrointestinal Diseases / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates / Q000009:adverse effects*; D000068836:Rivastigmine
D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine